Cerebral Infarction Drugs Market Analysis

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Cerebral Infarction Drugs Market Analysis

Distribution Channel (Hospitals, Drug Stores, Online Pharmacies)

The cerebral infarction drugs market is segmented and analyzed for demand and supply by distribution channel into hospitals, drug stores, online pharmacies, and others. Out of these four segments, the hospitals segment is estimated to gain the largest market share of about 56% in the year 2035. The growth of the segment can be attributed to the worldwide surging patient pool in hospitals to get efficient treatment and drugs for cerebrovascular disease, and ischemic strokes. For instance, in France, around 98,450 people were hospitalized for ischemic strokes and around 19,898 for intracerebral hemorrhage in 2019. In addition to this, the radically rising prevalence of the cerebrovascular disease among people, coupled with increasing stances of ischemic strokes are also estimated to boost the segment growth throughout the forecast period.

Drug Class {Tissue Plasminogen Activators (tPA), Anticoagulants}

The  cerebral infarction drugs market is also segmented and analyzed for demand and supply by drug class into tissue plasminogen activators (tPA), anticoagulants, and others. Amongst these three segments, the tissue plasminogen activators (tPA) segment is expected to garner a significant share of around 65% in the year 2035. The growth of the segment can be credited to the effectiveness of the tissue plasminogen activators (tPA) drugs in the treatment of cerebral infarction, and ischemic strokes, followed by its efficiency to restore blood flow by dissolving the clots in a blood vessel by activating the conversion of plasminogen to plasmin, an enzyme accountable for the breakdown of clots. On the other hand, the anticoagulants segment is projected to witness a notable CAGR during the forecast period, owing to their effectiveness as anticoagulants reduce the risk of an ischemic stroke or other embolic occurrences by more than two-thirds. Moreover, the surge in novel anticoagulant development is another factor anticipated to drive the growth of the market. For instance, Warfarin and some other newer anticoagulants function equally well in the long-term therapy of venous thromboembolism to avoid blood clots. One clot is avoided for every 15 persons who take any anticoagulant. 

Our in-depth analysis of the global market includes the following segments:

      By Diagnosis

  • Carotid Ultrasound
  • Cerebral Angiogram
  • Echocardiogram
  • Others

      By Drug Class

  • Tissue Plasminogen Activators (tPA)
  • Anticoagulants
  • Others

     By Distribution Channel

  • Hospitals
  • Drug Stores
  • Online Pharmacies
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Risk of side effects associated with the treatment, and low awareness among people in emerging nations regarding the cerebral infarction are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by diagnosis, drug class, distribution channel, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying